About bavarian nordic a/s - BVNRY
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
BVNRY At a Glance
Bavarian Nordic A/S
Philip Heymans Alle 3
Hellerup, Capital Region 2900
| Phone | 45-33-26-83-83 | Revenue | 1.02B | |
| Industry | Pharmaceuticals: Major | Net Income | 214.05M | |
| Sector | Health Technology | 2023 Sales Growth | 130.051% | |
| Fiscal Year-end | 12 / 2024 | Employees | 1,379 | |
| View SEC Filings |
BVNRY Valuation
| P/E Current | 12.938 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.424 |
| Price to Sales Ratio | 1.97 |
| Price to Book Ratio | 1.34 |
| Price to Cash Flow Ratio | 12.421 |
| Enterprise Value to EBITDA | 5.92 |
| Enterprise Value to Sales | 1.721 |
| Total Debt to Enterprise Value | 0.012 |
BVNRY Efficiency
| Revenue/Employee | 742,562.872 |
| Income Per Employee | 155,217.556 |
| Receivables Turnover | 3.689 |
| Total Asset Turnover | 0.524 |
BVNRY Liquidity
| Current Ratio | 1.938 |
| Quick Ratio | 1.348 |
| Cash Ratio | 0.67 |
BVNRY Profitability
| Gross Margin | 64.072 |
| Operating Margin | 21.219 |
| Pretax Margin | 21.013 |
| Net Margin | 20.903 |
| Return on Assets | 10.962 |
| Return on Equity | 16.733 |
| Return on Total Capital | 13.776 |
| Return on Invested Capital | 16.58 |
BVNRY Capital Structure
| Total Debt to Total Equity | 1.405 |
| Total Debt to Total Capital | 1.386 |
| Total Debt to Total Assets | 1.012 |
| Long-Term Debt to Equity | 0.955 |
| Long-Term Debt to Total Capital | 0.942 |
Bavarian Nordic A/S in the News
Bavarian Nordic promises to increase monkeypox vaccine production as supply shrinks
The producer of the only approved monkeypox vaccine is promising to increase the production of vaccine doses as supply falters and cases increase.